Fiche publication
Date publication
novembre 2015
Journal
Anti-cancer drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FUMOLEAU Pierre
,
Pr PIVOT Xavier
Tous les auteurs :
Pivot X, Aulagner G, Blay JY, Fumoleau P, Kaliski A, Sarkozy F, Limat S
Lien Pubmed
Résumé
Trastuzumab has transformed the treatment of HER2-positive breast cancer. Because of impending European patent expiry in 2017, numerous trastuzumab biosimilars are currently undergoing comparability exercises for marketing authorization. Although biosimilar products have been approved in Europe since 2006, many obstacles are expected for trastuzumab, resulting from its nature as a monoclonal antibody, its impact on overall survival, and its extensive biochemical complexities. Unsolved questions need to be addressed for the evaluation of biosimilars' activity in terms of appropriate clinical endpoint definitions for such anticancer drugs, specific assessment pathways and comparative testing of biosimilars, untested ensuing de facto combination of trastuzumab biosimilars with cytotoxics, and immunogenicity monitoring among immunocompromised patients. In such a context of uncertainties, the recent approval by the French parliament of biosimilar substitution, which would allow dispensing trastuzumab biosimilars in place of the originator, should interrogate the oncological community. A think tank of experts was created to delineate specificities and challenges stemming from trastuzumab biosimilars.
Mots clés
Antineoplastic Agents, therapeutic use, Biosimilar Pharmaceuticals, therapeutic use, Breast Neoplasms, drug therapy, Drugs, Generic, therapeutic use, Europe, Humans, Molecular Targeted Therapy, Receptor, ErbB-2, metabolism, Trastuzumab, therapeutic use
Référence
Anticancer Drugs. 2015 Nov;26(10):1009-16
